Navigation Links
Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages
Date:5/6/2009

Contract's Annual Value Estimated to Range from $1.5 Million - $3 Million

PRINCETON, N.J., May 6 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a manufacturer and marketer of advanced wound care products, today announced it has signed a new contract to supply private label adhesive bandages to one of the largest medical supply companies in the U.S. Annual revenues under the contract are expected to range between $1.5 to $3.0 million for Derma Sciences. Shipments to the customer will begin in the third quarter of 2009.

"We are delighted to formally announce this new contract, which is a milestone for Derma Sciences and illustrates the promise inherent in our recently acquired First Aid Division (FAD)," said CEO Ed Quilty. "We knew the FAD was a business unit with great potential, once the cost of manufacturing issues were sorted out. The contract illustrates the excellent operational condition of our FAD and is a prime example of why we purchased the division. We believe investors will now begin to see not only the improved costs associated benefits to our bottom line, but also will see accelerated top-line revenue growth as well."

The initial term of the contract is 18 months, with automatic one-year extensions. Either party can terminate the contract upon 90 days notice. Due to the nature of the private label agreement, the name of the medical supply company cannot be made public.

The contract was originally announced during the Company's fourth quarter, year-end results teleconference held on April 1 and sales to the customer were originally estimated to begin in the first quarter of 2010.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010.

For more information about Derma Sciences, Inc., visit http://www.dermasciences.com.

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

    Contact:

    Derma Sciences, Inc.
    Edward J. Quilty
    Chairman and CEO
    equilty@dermasciences.com
    (609) 514-4744

    Allen & Caron Inc
    Rudy Barrio (US Investors)
    r.barrio@allencaron.com
    (212) 691-8087

    Brian Kennedy (Media)
    brian@allencaron.com
    (212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. South Carolina Dermatologists Win Tennis Fans Attention With Free Skin Cancer Checks and Sun Safety Tips
2. Derma Sciences Announces Voluntary Delisting from the Defunct Boston Stock Exchange
3. Video: Jewelry Television(R) Introduces DermaGem(TM)
4. Dermatologists Encourage People to Screen the One You Love for Skin Cancer
5. Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat
6. American Academy of Dermatology Responds to FDA Decision Regarding Botulinum Toxin Products
7. Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts
8. South Carolina Dermatologists Will Serve Tennis Fans With Free Skin Checks and Sun Safety Tips
9. Topical Dermatological Product Development in the USA Workshop to Be Held on June 4, 2009 in East Brunswick, New Jersey, USA
10. New risk variant for atopic dermatitis identified
11. Pittsburgh Day Spa Welcomes Dermatologist, Ana C. Busquets, MD, FAAD And Is Accepting New Patients In Upper St. Clair And Cranberry Locations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... companies, has achieved ISO 17100:2015 certification following a comprehensive audit performed by ... globally recognized standard that establishes guidance for critical processes within translation, quality ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, ... technology behind SmartCap, which was founded in 2008 to address the limitations of ...
(Date:1/23/2017)... FL (PRWEB) , ... January 23, 2017 , ... Wooden and plastic balance boards have ... strength and improve balance. Kumo Board is the first and only balance board ... it to be soft and rigid at the same time as well as skill-level adjustable ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate ... about the benefits of making new water infrastructure a number one priority. “As we ... we expect water infrastructure to become a top priority of our new political change ...
(Date:1/23/2017)... ... 23, 2017 , ... Zachary Cattell, President of the Indiana ... industry expert at the 2017 Sector Summit hosted by Ivy Tech Community College ... Gerry Dick, will feature an employer and an association representative from five of ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... January 23, 2017 Varias ... enal) y el riesgo de ... a pabetalone    Resverlogix Corp. ("Resverlogix" ... preliminares de un ensayo en fase 1 con sede ... riñón (renal) severa. Los datos demostraron unos resultados importantes ...
(Date:1/23/2017)... January 23, 2017 Longer life expectancy and rising ... global market for medical device technologies. BCC Research reveals in ... Asia-Pacific region, should see strong growth due to rising ... incomes. Continue Reading ... ...
(Date:1/23/2017)... PALMA, Spain , January 23, ... a clinical-stage biopharmaceutical company focused on treatments for ... has been enrolled in the Phase IIb "CaLIPSO ... the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease ... ESRD patients, in the last stage of chronic ...
Breaking Medicine Technology: